Research projects

Alligator’s early-stage research projects include several projects within immuno-oncology, based on Alligator’s bispecific format RUBY™, with components created using ALLIGATOR-GOLD® and FIND®. Alligator is actively seeking collaboration partners on this programs.

For further information, please contact Peter Ellmark, Chief Scientific Officer.

Peter Ellmark
    • Independent in relation to the Company and its management: No
    • Independent in relation to major shareholders: Yes
    • Holdings in Alligator: 83,720 shares, 250,000 warrants in program TO 2022/2025 I and 40,000 warrants in program TO6.
    • Other current positions: None
    Updated 2022-07-18